Patents by Inventor William I. Bensinger

William I. Bensinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5262334
    Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.
    Type: Grant
    Filed: October 3, 1991
    Date of Patent: November 16, 1993
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ronald J. Berenson, William I. Bensinger
  • Patent number: 5225353
    Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.
    Type: Grant
    Filed: October 3, 1991
    Date of Patent: July 6, 1993
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ronald J. Berenson, William I. Bensinger
  • Patent number: 5215927
    Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.
    Type: Grant
    Filed: August 2, 1991
    Date of Patent: June 1, 1993
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ronald J. Berenson, William I. Bensinger
  • Patent number: 4614513
    Abstract: A method and apparatus are disclosed for treating a patient by removing immunoreactive substances from the patient's blood using microbial ligands such as Staphylococcus Protein A. The method of the present invention comprises removing blood from the patient, separating the removed blood into plasma and cellular components, passing the plasma component through an immunoadsorbent material to produce a treated plasma component, and returning the treated plasma component and the cellular component to the patient. The immunoadsorbent material comprises a microbial ligand such as Staphylococcus Protein A, or components thereof, covalently bonded to an inert and nondegradable support. The removing, separating, passing and returning steps are performed substantially continuously and simultaneously with one another.
    Type: Grant
    Filed: August 13, 1984
    Date of Patent: September 30, 1986
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: William I. Bensinger